Other Epithelial Bladder Tumors

Slide 1 · Other Epithelial Bladder Tumors

Squamous cell carcinoma | Adenocarcinoma | Small-cell carcinoma

Pathologic mechanisms · morphology · clinicopathologic interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish the three major non-urothelial epithelial bladder carcinoma categories.

Explain the injury–metaplasia–dysplasia sequence associated with bladder squamous carcinoma.

Relate morphology, precursor lesions, mixed histology, and invasion to diagnostic interpretation.

Recognize what the Robbins excerpt does not establish about immunophenotype and therapy.

Slide 3 · Tumors of the urinary bladder: Basic taxonomy

Urothelial neoplasms form the dominant epithelial group.

Other epithelial groups include squamous carcinoma, adenocarcinoma, mixed carcinoma, and small-cell carcinoma.

Mesenchymal tumors are classified separately from epithelial tumors.

Tumor family

Included groups

Epithelial

Urothelial; squamous; adenocarcinoma; mixed; small cell

Mesenchymal

Leiomyoma, sarcoma and other stromal lesions

Secondary involvement

Extension/metastasis from nonbladder malignancy

Slide 4 · Why non-urothelial tumors deserve separate recognition

They are less frequent than urothelial carcinoma but have distinct differentiation.

Pure tumors and mixed tumors with urothelial carcinoma must be distinguished.

Morphology and the relationship to precursor change provide the starting classification.

Squamous

Keratinization and squamous differentiation

Glandular

Gastrointestinal-like glandular morphology

Neuroendocrine / small cell

Small-cell pulmonary-like tumor phenotype

Slide 5 · Primary tumors versus secondary involvement

An epithelial malignancy in the bladder is not automatically bladder-derived.

Direct extension from cervix, uterus, prostate, or rectum is an important alternative.

True solid-tumor metastases to the bladder are described as very rare.

Primary bladder lesion

Tumor originates in the bladder.

Classification uses observed epithelial phenotype.

Adjacent mucosal abnormalities may offer context.

Secondary bladder involvement

Tumor extends from a neighboring organ.

Cervix, uterus, prostate, and rectum are cited.

The origin must be interpreted in anatomic context.

Slide 6 · Clinical presentation: The common entry point

Painless hematuria is the most common symptom of bladder cancer.

Frequency, urgency, and dysuria can accompany hematuria.

Symptoms alone cannot establish squamous, glandular, or small-cell differentiation.

Painless hematuria

Investigate bladder

Cystoscopy / cytology

Tissue diagnosis

Schematic — source-derived relationships; Not a clinical specimen

Slide 7 · Local consequences may reflect the tumor location

Bladder tumors may obstruct a ureteral orifice.

Pyelonephritis or hydronephrosis may develop following obstruction.

Symptoms and anatomic effects do not substitute for morphologic typing.

Tumor near ureteral orifice

Impaired urinary drainage

Hydronephrosis or pyelonephritis

Schematic — source-derived relationships; Not a clinical specimen

Slide 8 · Bladder wall layers frame tumor interpretation

Urothelium covers the surface; Lamina propria lies beneath it.

Muscularis propria is the detrusor muscle compartment.

Depth of invasion is essential to pathologic stage and clinical course.

Surface urothelium

Lamina propria

Muscularis propria

Perivesical soft tissue

Schematic of bladder wall compartments

Slide 9 · Different risk contexts require separate interpretation

Cigarette smoking is a major risk factor for bladder cancer overall.

Urinary schistosomiasis is specifically associated with squamous carcinoma in endemic areas.

Cyclophosphamide and pelvic irradiation are other bladder cancer–related exposures.

Context

Robbins association

Smoking

Major bladder cancer risk; also noted with small-cell carcinoma

S. haematobium

Chronic injury, squamous metaplasia, squamous carcinoma

Cyclophosphamide

Hemorrhagic cystitis and increased bladder cancer risk

Pelvic irradiation

Later urothelial carcinoma risk

Slide 10 · Squamous cell carcinoma: Defining context

Bladder squamous carcinoma resembles squamous malignancy at other anatomic sites.

Pure squamous carcinoma is different from urothelial carcinoma containing a squamous component.

An association with chronic irritation and infection.

Slide 11 · Squamous carcinoma is uncommon in the United States

That squamous carcinomas comprise 3%–7% of bladder cancers in the United States.

This is a United States estimate—not a global proportion.

Regional prevalence changes in settings where urinary schistosomiasis is endemic.

United States

Squamous carcinoma: 3%–7%.

Urothelial carcinoma predominates.

Schistosomiasis-endemic regions

Bladder squamous carcinoma is much more frequent.

The change is associated with S. Haematobium infection.

Slide 12 · Urinary schistosomiasis creates sustained epithelial injury

Schistosoma haematobium ova are deposited in the bladder wall.

The ova incite chronic inflammation.

Chronic mucosal injury sets the context for progressive squamous alteration.

S. Haematobium ova

Bladder wall deposition

Chronic inflammation

Squamous metaplasia

Schematic — source-derived relationships; Not a clinical specimen

Slide 13 · A multistep squamous precursor sequence

The textbook links chronic inflammation with squamous metaplasia, dysplasia, and neoplasia.

Progression is possible; Metaplasia alone does not imply that carcinoma is already present.

Represent the morphologic steps separately when examining a specimen.

Chronic irritation

Squamous metaplasia

Squamous dysplasia / CIS

Invasive squamous carcinoma

Schematic — source-derived relationships; Not a clinical specimen

Slide 14 · Squamous metaplasia is an adaptive epithelial change

Urothelium can be replaced by squamous epithelium in response to chronic injury.

The replacement as a more durable lining.

The change may be keratinizing or nonkeratinizing.

Normal urothelium

Specialized urinary lining.

An umbrella cell layer is a normal surface feature.

Squamous metaplasia

Squamous epithelium replaces urothelium.

A more durable response to chronic injury.

Slide 15 · Not all squamous epithelium in the bladder is abnormal

Glycogenated squamous epithelium normally occurs at the female bladder trigone.

It must be separated from injury-related keratinizing squamous metaplasia.

Anatomic site and type of epithelial maturation therefore matter.

Normal trigonal finding

Glycogenated squamous epithelium.

Recognized in females.

Injury-associated lesion

Keratinizing squamous metaplasia.

May be extensive and multifocal.

Slide 16 · Keratinizing squamous metaplasia and malignant potential

Extensive multifocal keratinizing metaplasia is a precursor to squamous dysplasia and carcinoma.

Both in situ and invasive squamous carcinoma as possible downstream lesions.

Keratinizing metaplasia therefore merits distinction from physiologic trigonal squamous epithelium.

Extensive keratinizing metaplasia

Squamous dysplasia

Squamous CIS

Invasive squamous carcinoma

Schematic — source-derived relationships; Not a clinical specimen

Slide 17 · Squamous dysplasia versus in situ carcinoma

Both lie on the dysplastic precursor spectrum.

Carcinoma in situ indicates cytologic malignancy confined to the epithelial compartment.

Invasion requires malignant cells to extend beyond the epithelial basement membrane.

Surface urothelium

Lamina propria

Muscularis propria

Perivesical soft tissue

Schematic of bladder wall compartments

Slide 18 · Why precursor mapping matters in squamous carcinoma

Atypical keratinizing mucosa can provide a mucosal precursor adjacent to a tumor.

Identify dysplasia or in situ change separately from invasive tumor.

The presence of a precursor helps interpret the injury-associated sequence.

Atypical keratinizing mucosa

Epithelial neoplasia

Infiltration of bladder wall

Schematic — source-derived relationships; Not a clinical specimen

Slide 19 · Two different bladder cancer developmental pathways

Non–muscle-invasive papillary urothelial cancers commonly involve growth-factor signaling activation.

The CIS-associated muscle-invasive pathway often involves disruption of TP53 and RB.

These general urothelial patterns should not be imposed automatically on every non-urothelial tumor.

Papillary urothelial pathway

FGFR3, RAS, PI 3-kinase alterations.

Often recurs; Less often becomes muscle invasive.

CIS-associated invasive pathway

TP53 and RB pathway disruption.

Associated with muscle-invasive disease.

Slide 20 · Pure squamous carcinoma versus mixed carcinoma

Mixed urothelial carcinoma containing areas of squamous carcinoma is more common than pure squamous carcinoma.

A diagnosis of a purely squamous tumor depends on assessment of the sampled neoplasm.

Do not assume any squamous differentiation excludes an accompanying urothelial component.

Pure squamous carcinoma

Squamous phenotype constitutes the described tumor.

No urothelial carcinoma component identified in evaluated tissue.

Mixed urothelial / squamous tumor

Urothelial carcinoma and squamous areas coexist.

Recognizing both components changes descriptive classification.

Slide 21 · The gross appearance of squamous carcinoma is often invasive

Most squamous carcinomas as invasive lesions.

One macroscopic form is a fungating mass protruding into the bladder lumen.

An alternative pattern is infiltrative and ulcerative.

Fungating projection

Infiltrative / ulcerative

Conceptual gross-pattern schematics — not clinical specimen images

Slide 22 · Fungating tumors: An exophytic invasive pattern

A fungating mass projects into the lumen.

Gross projection does not by itself determine whether the muscularis propria is involved.

Histologic evaluation is still needed to establish invasion depth.

Fungating projection

Conceptual gross-pattern schematics — not clinical specimen images

Slide 23 · Infiltrative and ulcerative squamous tumors

The lesion may extend within the bladder wall and ulcerate the overlying surface.

Surface ulceration is not a substitute for histologic staging.

The wall layers provide the anatomic framework for reporting extent.

Infiltrative / ulcerative

Conceptual gross-pattern schematics — not clinical specimen images

Slide 24 · Squamous histology spans a differentiation spectrum

Well-differentiated tumors produce abundant keratin.

At the anaplastic end, squamous differentiation may only be focal.

The degree of differentiation is not uniform among all squamous carcinomas.

Well differentiated

Intermediate

Anaplastic

Progressively less overt keratinizing differentiation

Slide 25 · Well-differentiated squamous carcinoma

Abundant keratin formation is emphasized in the Robbins description.

Keratin production is a morphologic expression of squamous differentiation.

The assessment still requires attention to invasion and any nonsquamous tumor component.

Slide 26 · Anaplastic squamous carcinoma: Sparse clues

Some tumors show only focal evidence of squamous differentiation.

Limited squamous foci are easier to overlook than abundant keratin production.

A restricted sample may not reveal the full differentiation spectrum.

Extensive squamous differentiation

Abundant keratin; Conspicuous squamous identity.

Focal squamous differentiation

Only limited areas may establish phenotype.

Evaluate other available tumor regions.

Slide 27 · Morphology and tumor sampling: An interpretive boundary

The source explicitly recognizes mixed tumors and focal squamous differentiation.

Accordingly, phenotype in a limited fragment may not represent the entire mass.

Interpretation should distinguish observed findings from claims about unsampled tissue.

Examine sampled tumor

Identify squamous areas

Search sampled tissue for other components

State demonstrated pattern

Schematic — source-derived relationships; Not a clinical specimen

Slide 28 · Teaching case: Chronic irritative disease and a bladder mass

HYPOTHETICAL TEACHING CASE

Hypothetical: An older patient from a schistosomiasis-endemic region has hematuria and an ulcerated bladder mass.

Tissue shows keratinizing carcinoma next to atypical keratinizing mucosa.

Question: Which pathogenetic sequence is most consistent with these observations?

Interpretation requires separating observed evidence from diagnostic inference.

Slide 29 · Case interpretation: Separate evidence from inference

Observed evidence: Keratinizing carcinoma, adjacent atypical mucosa, and an ulcerated mass.

Source-supported inference: The pattern is compatible with squamous carcinoma arising in an injury-related metaplastic field.

Do not infer a specific infection in an individual patient solely from tumor morphology.

Observed

Squamous differentiation.

Atypical keratinizing epithelium.

Ulcerated lesion.

Interpretation

Compatible precursor sequence.

Etiologic attribution requires clinical evidence.

Slide 30 · Adenocarcinoma of the bladder is rare

Adenocarcinoma is listed as a distinct bladder epithelial tumor category.

Bladder adenocarcinoma as rare.

Its morphology closely resembles adenocarcinoma in the gastrointestinal tract.

Slide 31 · Adenocarcinoma: The glandular differentiation problem

The textbook stresses histologic identity with gastrointestinal adenocarcinomas.

Glandular appearance establishes a phenotype, not automatically the organ of origin.

Bladder-primary disease must be separated from extension by a nearby gastrointestinal tumor.

Morphologic question

Is the tumor gland-forming / adenocarcinomatous?

How closely does it resemble intestinal cancer?

Anatomic origin question

Does the lesion arise in the bladder?

Could it extend from the rectum or another organ?

Slide 32 · Intestinal metaplasia is a relevant epithelial precursor

Extensive, multifocal intestinal metaplasia as a precursor to bladder adenocarcinoma.

The precursor is addressed in the related section on metaplastic lesions.

This is a risk relationship—not a claim that every glandular lesion becomes malignant.

Chronic mucosal injury

Intestinal metaplasia

Precursor field

Possible adenocarcinoma

Schematic — source-derived relationships; Not a clinical specimen

Slide 33 · Von Brunn nests: The starting epithelial architecture

Urothelial nests can extend downward into the lamina propria.

These are termed von Brunn nests.

Their centers may later undergo glandular change or cystic retraction.

Surface urothelium

Downward urothelial nests

Schematic (not histology)

Slide 34 · Cystitis glandularis: A benign glandular mimic

Central cells within urothelial nests acquire a cuboidal or columnar appearance.

Robbins calls this cystitis glandularis.

A glandular lining in the bladder is therefore not synonymous with invasive adenocarcinoma.

Surface urothelium

Cuboidal / columnar central metaplasia

Schematic (not histology)

Slide 35 · Cystitis cystica: A cystic rather than glandular pattern

Central nest cells retract, leaving cystic spaces.

The resulting spaces are lined by flattened urothelium.

The lesion can coexist with cystitis glandularis.

Surface urothelium

Cystic central retraction

Schematic (not histology)

Slide 36 · Cystitis cystica et glandularis: Frequent coexistence

The cystic and glandular metaplastic processes often coexist.

The combined term cystitis cystica et glandularis reflects this overlap.

Histologic context prevents overcalling a benign reactive process as cancer.

Cystitis cystica

Retracted nest centers.

Cystic space with flattened lining.

Cystitis glandularis

Cuboidal or columnar metaplasia.

Glandular-appearing epithelial nests.

Slide 37 · Glandular change and carcinoma require distinction

Benign glandular metaplasia is not itself a diagnosis of adenocarcinoma.

Extensive multifocal intestinal metaplasia has a recognized precursor association.

An invasive adenocarcinoma must be characterized on its own malignant architecture and context.

Glandular finding

Determine metaplasia vs carcinoma

Evaluate invasion and origin

Schematic — source-derived relationships; Not a clinical specimen

Slide 38 · Primary bladder adenocarcinoma versus rectal extension

A glandular tumor in the bladder can resemble a gastrointestinal primary histologically.

The rectum among common adjacent sources of direct malignant extension.

Anatomic relationship is therefore indispensable to assigning primary site.

Possible bladder primary

Bladder epithelial tumor with adenocarcinoma morphology.

Evaluate associated bladder mucosa.

Possible rectal extension

Rectal tumor directly involving bladder.

Morphologic similarity alone cannot settle the origin.

Slide 39 · Teaching case: A gland-forming bladder tumor

HYPOTHETICAL TEACHING CASE

Hypothetical: Bladder biopsy contains carcinoma with intestinal-type glandular morphology.

Imaging also shows a mass adjacent to the rectum.

Question: What does morphology establish, and what remains unresolved?

Interpretation requires separating observed evidence from diagnostic inference.

Slide 40 · Adenocarcinoma case: Scope the conclusion correctly

The gland-forming pattern supports a diagnosis of adenocarcinoma.

It cannot alone demonstrate whether the lesion started in bladder or rectum.

Correlate pathology with the tumor epicenter and adjacent-organ findings.

Slide 41 · Small-cell carcinoma: A distinct epithelial malignancy

Small-cell carcinoma occasionally arises in the urinary bladder.

Robbins says its histologic appearance is indistinguishable from small-cell carcinoma of the lung.

It should not be conflated with urothelial carcinoma solely because both occur in the bladder.

Slide 42 · Small-cell appearance does not prove lung origin

The term “small-cell carcinoma” denotes a morphologic tumor phenotype.

The textbook explicitly recognizes primary bladder occurrence.

Anatomic and clinical context remains necessary when assessing site of origin.

Morphology

Small-cell phenotype analogous to pulmonary small-cell carcinoma.

Site attribution

Bladder may be the primary site.

Morphology alone is not site-specific.

Slide 43 · Small-cell carcinoma often has mixed histology

Bladder small-cell carcinoma often arises adjacent to urothelial carcinoma.

Squamous carcinoma or adenocarcinoma may also be present alongside it.

Such admixture should be recognized rather than flattened into one generic tumor label.

Urothelial area

One possible associated epithelial component

Squamous / glandular area

Other epithelial components may coexist

Small-cell area

Distinct small-cell phenotype

Slide 44 · Age and smoking association in small-cell carcinoma

Bladder small-cell carcinoma with advanced age and smoking.

Smoking is also a major bladder cancer risk factor overall.

An exposure association does not replace histologic diagnosis.

Clinical context

Advanced age / smoking

Bladder lesion

Morphologic assessment

Schematic — source-derived relationships; Not a clinical specimen

Slide 45 · Neuroendocrine differentiation as a conceptual origin

Bladder small-cell carcinoma as arising from neuroendocrine cells.

This distinguishes its stated origin from ordinary squamous or glandular epithelial differentiation.

No specific immunohistochemical panel is provided in the supplied passage.

Squamous

Squamous differentiation

Glandular

Adenocarcinomatous differentiation

Neuroendocrine

Small-cell carcinoma lineage

Slide 46 · TP53 and RB alterations in small-cell carcinoma

Very aggressive bladder small-cell carcinomas commonly harbor loss-of-function mutations in TP53 and RB.

The altered tumor suppressors are also highlighted in the muscle-invasive urothelial pathway.

A shared molecular alteration does not mean the tumor types are identical.

TP53 / RB loss of function

Tumor-suppressor disruption

Aggressive small-cell carcinoma

Schematic — source-derived relationships; Not a clinical specimen

Slide 47 · Compare two major molecular themes

Papillary non–muscle-invasive urothelial cancer: Activating growth-factor pathway alterations.

Bladder small-cell carcinoma: Common TP53 and RB loss-of-function alterations.

Robbins does not supply a defining molecular signature for every squamous or glandular bladder carcinoma.

Tumor pattern

Highlighted molecular alteration

Non–muscle-invasive papillary urothelial

FGFR3, RAS, PI 3-kinase pathway activation

Muscle-invasive urothelial / CIS pathway

TP53 and RB disruption

Bladder small-cell

Common TP53 and RB loss of function

Pure squamous / bladder adenocarcinoma

Not specified in the targeted textbook excerpt

Slide 48 · Clinical meaning of an aggressive small-cell phenotype

Robbins explicitly describes bladder small-cell carcinoma as very aggressive.

Its occurrence with other epithelial components makes careful morphologic recognition essential.

General urothelial carcinoma survival figures must not be assigned to small-cell carcinoma without supporting data.

Slide 49 · Teaching case: A bladder carcinoma with two patterns

HYPOTHETICAL TEACHING CASE

Hypothetical: A bladder tumor shows small-cell carcinoma adjacent to an otherwise recognizable urothelial carcinoma.

The patient has a long smoking history.

Question: Which two source-supported features should be recorded?

Interpretation requires separating observed evidence from diagnostic inference.

Slide 50 · Case interpretation: Document both components

A small-cell component is a separate morphologic finding.

Coexisting urothelial carcinoma should not be hidden by a broad “bladder cancer” label.

The tumor can be contextualized by age and smoking without making unsupported molecular or treatment claims.

Reportable observations

Small-cell carcinoma phenotype.

Associated urothelial carcinoma.

Context, not proof

Age and smoking association.

TP53/RB alterations are common, not obligatory.

Slide 51 · Three tumor types: An integrated comparison

The three categories are defined by different epithelial phenotypes.

Mixed histology and overlapping clinical features complicate classification.

Feature

Squamous cell

Adenocarcinoma

Small cell

Frequency

3%–7% of US bladder cancers

Rare

Occasional

Characteristic context

Chronic irritation; schistosomiasis

Intestinal metaplasia precursor

Advanced age; smoking

Typical description

Keratinization; invasive mass

GI-like histology

Lung small-cell–like

Other components

Often mixed with urothelial

May appear in mixed carcinoma

Often adjacent to other epithelial types

Slide 52 · Precursor associations should not be generalized

Keratinizing squamous metaplasia can precede dysplasia and squamous carcinoma.

Extensive multifocal intestinal metaplasia is a precursor to adenocarcinoma.

The small-cell passage provides no corresponding metaplastic precursor sequence.

Histotype

Precursor information supported by Robbins

Squamous cell carcinoma

Keratinizing metaplasia → dysplasia / CIS

Adenocarcinoma

Extensive multifocal intestinal metaplasia

Small-cell carcinoma

No precursor sequence specified in passage

Slide 53 · Phenotype, risk, and primary site are different questions

Phenotype: What differentiation is present in the tumor?

Risk context: Which exposures or injury patterns are linked with that histotype?

Primary site: Did the tumor originate in the bladder or extend from elsewhere?

Morphology

Clinical / exposure history

Anatomic correlation

Integrated diagnosis

Schematic — source-derived relationships; Not a clinical specimen

Slide 54 · Cystoscopy and urine cytology: Roles and limits

Painless hematuria prompts clinical investigation by cystoscopy and/or urine cytology.

Cystoscopy assesses visible bladder mucosal abnormalities.

The specific epithelial histotype and depth of invasion require tissue-based interpretation.

Hematuria

Cystoscopy / urine cytology

Histologic assessment

Tumor type and invasion

Schematic — source-derived relationships; Not a clinical specimen

Slide 55 · Invasion is defined relative to the bladder wall

Lamina propria invasion corresponds to pT1 in the supplied AJCC 8th-edition staging table.

Muscularis propria involvement corresponds to pT2.

Perivesical soft-tissue invasion is pT3; Specified adjacent-organ or pelvic-wall involvement is pT4.

Surface urothelium

Lamina propria

Muscularis propria

Perivesical soft tissue

Schematic of bladder wall compartments

Slide 56 · Selected pT categories from the supplied AJCC 8th edition

The table concerns depth/anatomic extent, not epithelial differentiation.

It provides a common staging language for carcinoma of the urinary bladder.

Primary tumor category

Meaning

Ta / Tis

Noninvasive papillary carcinoma / flat urothelial CIS

T1

Lamina propria invasion

T2

Muscularis propria invasion

T3

Perivesical soft-tissue invasion

T4

Extension into specified adjacent organs or walls

Slide 57 · Why muscularis propria invasion changes the discussion

Depth of invasion as the most important prognostic factor in invasive bladder cancer.

Muscle-invasive disease has substantially greater potential for regional and distant spread.

Staging must be recorded independently of histologic subtype.

Tumor breaches lamina propria

Muscularis propria involvement

Higher-risk invasive disease

Schematic — source-derived relationships; Not a clinical specimen

Slide 58 · Mixed epithelial tumors: A structured examination

Identify each demonstrated epithelial component rather than assuming a pure histotype.

Document squamous, glandular, urothelial, or small-cell features actually seen.

Separate cell type from depth of invasion and primary-site attribution.

Morphologic phenotype

Pure or mixed?

Invasion depth?

Bladder primary or secondary?

Schematic — source-derived relationships; Not a clinical specimen

Slide 59 · Interpretive pitfalls to avoid

Do not mistake physiologic glycogenated trigonal squamous epithelium for high-risk keratinizing metaplasia.

Do not equate cystitis glandularis with adenocarcinoma.

Do not classify a mixed urothelial–squamous carcinoma as necessarily pure squamous.

Do not equate small-cell appearance with a lung primary.

Pitfall

Correct discriminating question

Trigonal squamous lining

Physiologic glycogenated or keratinizing injury related?

Glandular epithelium

Metaplastic or invasive adenocarcinoma?

Squamous tumor area

Pure squamous or mixed with urothelial cancer?

Small-cell tumor

Primary bladder or involvement from elsewhere?

Slide 60 · Integrated teaching case: Classify without overreaching

HYPOTHETICAL TEACHING CASE

Hypothetical: A bladder lesion contains invasive carcinoma with extensive keratin production, focal urothelial carcinoma, and muscularis propria invasion.

There is a history of chronic bladder irritation.

Question: What should be distinguished in histotype, risk context, and stage?

Interpretation requires separating observed evidence from diagnostic inference.

Slide 61 · Integrated case: A defensible interpretation

Histotype: Both urothelial and squamous components are observed, so avoid claiming pure squamous carcinoma.

Risk context: Chronic irritation is associated with squamous differentiation but is not uniquely causal.

Extent: Muscularis propria invasion is the defining feature of pT2 in the supplied staging system.

Tumor classification

Mixed urothelial and squamous carcinoma

Predisposing context

Chronic irritation is associated, not diagnostic

Anatomic extent

Muscularis propria involved: PT2

Slide 62 · Essential conclusions

Squamous carcinoma is linked to chronic injury, especially schistosomiasis, and spans a wide differentiation spectrum.

Bladder adenocarcinoma is rare, resembles gastrointestinal adenocarcinoma, and requires attention to glandular mimics and site of origin.

Small-cell carcinoma is an aggressive, often mixed tumor associated with smoking and common TP53/RB loss.

Morphologic type, precursor field, anatomic origin, and invasion depth are complementary—not interchangeable—diagnostic dimensions.

Slide 63 · Primary reading and scope of evidence

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th edition (2026). Chapter 21: The Lower Urinary Tract and Male Genital System.

Principal section: “Other Epithelial Bladder Tumors”; related bladder neoplasm, metaplasia, secondary tumor and staging material.

Conceptual schematics and hypothetical cases are original teaching constructions; no synthetic microscopy is presented as diagnostic evidence.

The supplied material does not provide a validated immunohistochemical panel or treatment algorithm for each of these uncommon histotypes.